Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, CEO & President | 1.1M | -- | 1973 |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical & Business Operations | 675k | -- | 1960 |
| Mr. Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy | 412.5k | -- | 1962 |
| Mr. John W. Townsend CPA | Chief Financial Officer | 197.86k | -- | 1962 |
Unicycive Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Corporate Governance
Upcoming Events
March 31, 2025 at 11:00 AM UTC
Unicycive Therapeutics, Inc. Earnings Date
Recent Events
November 13, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
July 11, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission